This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
US researchers examined geneexpression in more than a million brain cells collected post-mortem from 191 donors. Those with schizophrenia and older adults were found to have a comparitively reduced expression of specific genes in both […]
The authors of the study say their research is the first to link COVID-19 to molecular signatures of brain aging. “We observed that geneexpression in the brain tissue of patients who died […].
A subgroup analysis revealed even greater improvement in patients with high interferon-1 (IFN-1) geneexpression, a known indicator of disease severity, with a -2.78 The cenerimod 4 mg group showed a significant improvement of -4.04 in mSLEDAI-2K compared to placebo. reduction compared to placebo.
XTALKS CLINICAL EDGE: Issue 2 — Elixirgen Therapeutics’ Interview Xtalks Clinical Edge is a magazine for clinicalresearch professionals and all who want to be informed about the latest trends and happenings in clinical trials.
Further evidence of its potential efficacy as a drug candidate was also established based on diminished hypothalamic inflammatory geneexpression. Marks is an established physician scientist with experience leading clinicalresearch studies. About the author. Dr. Daniel L.
ClinicalResearch Strategies for Fructose Metabolism. Measuring visceral and hepatic fat in clinical practice and clinicalresearch. Opiate-like effects of sugar on geneexpression in reward areas of the rat brain. Role of insulin resistance and diet in acne. Indian J Dermatol Venereol Leprol.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content